The global burden of cancer remains high, with tens of millions of new cases being diagnosed and millions of lives being lost to the disease each year. Chemotherapy and targeted therapies have limitations and can cause serious side effects. Nucleic acids, including DNA and RNA, offer immense potential as innovative therapeutics for the treatment of cancer and various diseases, but their delivery to the target cells of tissues is very challenging. Various carriers have been developed to enhance delivery, including lipid nanoparticles and viral vectors, but challenges such as immunogenicity and off-target accumulation remain. Cell-mediated delivery systems offer important benefits, including a longer circulation time, enhanced homing to the target site, improved biocompatibility, and the possibility of engineering the cell carriers to sense and respond to disease-associated biomarkers. This paper provides an overview of currently disclosed cell-based delivery systems and proposes improvements to address their limitations. A versatile delivery system that could revolutionize medicine by achieving targeted delivery of therapeutic nucleic acids to specific tissues while minimizing side effects is presented.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...JohnJulie1
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...daranisaha
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients. Drug repurposing sometimes-termed drug repositioning is a strategy of discovery and redeveloping existing drugs for new therapeutic purposes. This novel approach is highly efficient, considerably cuts research and development costs, reduces the drug development timeline, maximizes therapeutic value and consequently increases success rate with minimum risk of failure.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...semualkaira
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...semualkaira
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
INNOVATIVE MEDICINES, TECHNOLOGIES AND APPROACHES FOR IMPROVING PATIENTS' HE...Jing Zang
Despite remarkable scientific and technological achievements during the 20th century, the 21st century has already witnessed additional new and profound changes in all areas of medical science and research, including innovations and discoveries in biology, cellular biology, genomics and proteomics, pharmaceuticals, medical devices, and information technology. This review is an up-date on some of the existing therapies, drug delivery technologies, and approaches that aimed to improve patients’ health care and quality of their life.
ciclo autonomico-short paper - Witfor 2016 paper_42.. ..
This paper presents an ongoing project to develop a biocomputational platform to analyze genomic data from cancer patients and bacteria in Costa Rica. The platform will integrate genomic data processing, prediction of drug sensitivity, and identification of new therapeutic targets. It will use pattern recognition techniques and mathematical models on genomic and drug response data to predict personalized therapy. Preliminary results include databases to store cancer and bacteria genomic data, and tools for exploring relationships between genomic features and drug responses. The platform aims to help identify optimal personalized treatments to overcome drug resistance in cancer and bacterial infections.
implantable drug delivery system in cancer targetting.pptxanjaliKM13
Implantable drug delivery systems have the potential to revolutionize cancer treatment by providing localized drug delivery and targeting. Conventional cancer treatments have limitations in terms of precision and side effects. Implantable devices can be used to deliver targeted radiation therapy or drugs directly to tumor sites, allowing for precise localized treatment. Some common types of implantable devices used in cancer treatment include implantable sensors, radiation devices, and drug delivery systems. Challenges remain regarding device reliability, costs, and limited applicability, but ongoing advancements offer hope for improving treatment outcomes and quality of life in the fight against cancer.
The Immunotherapy in Cancer Treatment Occurring Advancement in Using the Immu...ijtsrd
The cancer immunity cycle is characterized by various stimulatory and inhibitory factors, which together regulate the immune response and halt the extreme response that may lead to autoimmune disease. Immunotherapy of cancer has rejuvenated the field of tumor immunology and revolutionized treatment options. In the present review, we discussed the recent advances in different molecular mechanisms of cancer immunotherapy. An immunotherapy is a advanced treatment that boosts humoral and cellular immunity rather than using chemotherapy or radiation based strategy associated with non specific targets and toxic effects on normal cells. Immune checkpoint inhibitors and T cell based immunotherapy have already exhibited significant effects against solid tumor and leukemia. Tumor cells that escape immune surveillance create a major obstacle to acquiring an effective immune response in cancer patients. The previous year’s worldview for cancer treatment has advanced from general to more precise therapeutic approaches. Chemotherapies were first distinguished as the most reliable and brief therapy with promising outcomes in cancer patients. It is a breast cancer is the most commonly diagnosed cancer in women and is a leading cause of cause death in women worldview. Despite the available treatment options, such as surgery, chemotherapy, radiotherapy, endocrine therapy and molecular targeted therapy, breast cancer treatment remains a challenge. The FDA approvals of immunotherapeutic drugs underscore the progress made. Antibody engineering has further advanced the production of specialized and potent humanized monoclonal antibodies for clinical use. Mr. Jayesh R. Tundlayat | Mr. Yogesh V. Vaidya "The Immunotherapy in Cancer Treatment: Occurring Advancement in Using the Immune System to Combat Cancer" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-8 | Issue-1 , February 2024, URL: https://www.ijtsrd.com/papers/ijtsrd62386.pdf Paper Url: https://www.ijtsrd.com/pharmacy/pharmaceutics/62386/the-immunotherapy-in-cancer-treatment-occurring-advancement-in-using-the-immune-system-to-combat-cancer/mr-jayesh-r-tundlayat
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...JohnJulie1
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...daranisaha
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients. Drug repurposing sometimes-termed drug repositioning is a strategy of discovery and redeveloping existing drugs for new therapeutic purposes. This novel approach is highly efficient, considerably cuts research and development costs, reduces the drug development timeline, maximizes therapeutic value and consequently increases success rate with minimum risk of failure.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...semualkaira
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...semualkaira
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
INNOVATIVE MEDICINES, TECHNOLOGIES AND APPROACHES FOR IMPROVING PATIENTS' HE...Jing Zang
Despite remarkable scientific and technological achievements during the 20th century, the 21st century has already witnessed additional new and profound changes in all areas of medical science and research, including innovations and discoveries in biology, cellular biology, genomics and proteomics, pharmaceuticals, medical devices, and information technology. This review is an up-date on some of the existing therapies, drug delivery technologies, and approaches that aimed to improve patients’ health care and quality of their life.
ciclo autonomico-short paper - Witfor 2016 paper_42.. ..
This paper presents an ongoing project to develop a biocomputational platform to analyze genomic data from cancer patients and bacteria in Costa Rica. The platform will integrate genomic data processing, prediction of drug sensitivity, and identification of new therapeutic targets. It will use pattern recognition techniques and mathematical models on genomic and drug response data to predict personalized therapy. Preliminary results include databases to store cancer and bacteria genomic data, and tools for exploring relationships between genomic features and drug responses. The platform aims to help identify optimal personalized treatments to overcome drug resistance in cancer and bacterial infections.
implantable drug delivery system in cancer targetting.pptxanjaliKM13
Implantable drug delivery systems have the potential to revolutionize cancer treatment by providing localized drug delivery and targeting. Conventional cancer treatments have limitations in terms of precision and side effects. Implantable devices can be used to deliver targeted radiation therapy or drugs directly to tumor sites, allowing for precise localized treatment. Some common types of implantable devices used in cancer treatment include implantable sensors, radiation devices, and drug delivery systems. Challenges remain regarding device reliability, costs, and limited applicability, but ongoing advancements offer hope for improving treatment outcomes and quality of life in the fight against cancer.
The Immunotherapy in Cancer Treatment Occurring Advancement in Using the Immu...ijtsrd
The cancer immunity cycle is characterized by various stimulatory and inhibitory factors, which together regulate the immune response and halt the extreme response that may lead to autoimmune disease. Immunotherapy of cancer has rejuvenated the field of tumor immunology and revolutionized treatment options. In the present review, we discussed the recent advances in different molecular mechanisms of cancer immunotherapy. An immunotherapy is a advanced treatment that boosts humoral and cellular immunity rather than using chemotherapy or radiation based strategy associated with non specific targets and toxic effects on normal cells. Immune checkpoint inhibitors and T cell based immunotherapy have already exhibited significant effects against solid tumor and leukemia. Tumor cells that escape immune surveillance create a major obstacle to acquiring an effective immune response in cancer patients. The previous year’s worldview for cancer treatment has advanced from general to more precise therapeutic approaches. Chemotherapies were first distinguished as the most reliable and brief therapy with promising outcomes in cancer patients. It is a breast cancer is the most commonly diagnosed cancer in women and is a leading cause of cause death in women worldview. Despite the available treatment options, such as surgery, chemotherapy, radiotherapy, endocrine therapy and molecular targeted therapy, breast cancer treatment remains a challenge. The FDA approvals of immunotherapeutic drugs underscore the progress made. Antibody engineering has further advanced the production of specialized and potent humanized monoclonal antibodies for clinical use. Mr. Jayesh R. Tundlayat | Mr. Yogesh V. Vaidya "The Immunotherapy in Cancer Treatment: Occurring Advancement in Using the Immune System to Combat Cancer" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-8 | Issue-1 , February 2024, URL: https://www.ijtsrd.com/papers/ijtsrd62386.pdf Paper Url: https://www.ijtsrd.com/pharmacy/pharmaceutics/62386/the-immunotherapy-in-cancer-treatment-occurring-advancement-in-using-the-immune-system-to-combat-cancer/mr-jayesh-r-tundlayat
1. The document discusses using machine learning to optimize microfluidic platforms for cancer research. It reviews how microfluidics has been used for circulating tumor cell isolation and modeling tumor microenvironments.
2. Machine learning can help reveal the causality between different factors in cancer metastasis by analyzing large datasets from microfluidic experiments. This can help push research to a higher level.
3. The integration of machine learning and microfluidics, known as intelligent microfluidics, allows microfluidic platforms to reach their full potential by using machine learning techniques like feature extraction, classification, prediction, and optimization.
Nanotechnology in Targeted Drug Delivery.pdfAzeem Muhammed
This document discusses nanotechnology for targeted drug delivery and therapeutics. It describes how nanocarriers such as liposomes, polymeric nanoparticles, micelles, dendrimers, and hydrogels can be used as drug delivery platforms. These nanocarriers protect drugs, allow for controlled release, and can be modified for targeted delivery through conjugation of ligands. Many nanocarrier drug delivery systems are currently in clinical trials for applications such as cancer therapy and treatment of other diseases.
This white paper discusses improving the clinical development of cancer immunotherapies. It outlines the current immunotherapy landscape including checkpoint inhibitors, adoptive T cell therapies, cancer vaccines, and biomarkers. The paper emphasizes that while immunotherapy has promising results for some patients and cancer types, more research is needed to understand which patients will benefit most from which approaches and how to best leverage various immune system components in the fight against cancer. Operational considerations and cautions for clinical development are also discussed.
This document describes a new cancer therapy technique using tunable, monochromatic X-rays being developed by the company MXISystems. The technique shows promise in precisely targeting radiation therapy to cancer cells while sparing healthy tissue. However, commercializing the technology faces challenges including high capital costs, lack of supply chain for key components, and investor reluctance over perceived long-term risk. The document applies the framework of accelerated radical innovation to analyze MXISystems' innovation and determine how to accelerate its widespread clinical use by addressing challenges it faces in commercialization.
Global dendritic cell cancer vaccine market outlook 2020KuicK Research
“Global Dendritic Cell Cancer Vaccine Market Outlook 2020” Report highlights:
Introduction & Mechanism of Action of Dendritic Cells
New Vaccine Strategies That Exploit Dendritic Cells Biochemistry
Dendritic Cell Cancer Vaccine Market & Clinical Insight
Comparative Insight of Dendritic Cell Vaccines & Other Class of Vaccines
Dendritic Cell Cancer Vaccine Pipeline by Country, Company, Indication & Phase
Dendritic Cell Cancer Vaccine Clinical Pipeline: 58 Vaccines
Majority in Phase I/II & Phase II Clinical Trials: 12 Vaccines
1) The document discusses precision medicine in cancer treatment, which is a medical model that takes into account individual variability in genes, lifestyle, and environment to tailor treatment for each patient.
2) Precision medicine aims to improve cancer treatment outcomes by using biomarkers and genetic/molecular analysis to identify the specific causes of a patient's cancer and select targeted therapies.
3) This approach could help increase survival rates, reduce side effects, and improve overall treatment efficacy compared to traditional one-size-fits-all cancer care.
Cancer is one of the deadliest diseases in the world and is responsible for around 13% of all deaths worldwide.
Cancer incidence rate is growing at an alarming rate in the world. Despite the fact that cancer is
preventable and curable in early stages, the vast majority of patients are diagnosed with cancer very late.
Furthermore, cancer commonly comes back after years of treatment. Therefore, it is of paramount
importance to predict cancer recurrence so that specific treatments can be sought. Nonetheless,
conventional methods of predicting cancer recurrence rely solely on histopathology and the results are not
very reliable. The microarray gene expression technology is a promising technology that couldpredict
cancer recurrence by analyzing the gene expression of sample cells. The microarray technology allows
researchers to examine the expression of thousands of genes simultaneously. This paper describes a stateof-
the-art machine learning based approach called averaged one-dependence estimators with subsumption
resolution to tackle the problem of predicting, from DNA microarray gene expression data, whether a
particular cancer will recur within a specific timeframe, which is usually 5 years. To lower the
computational complexity, we employ an entropy-based geneselection approach to select relevant
prognosticgenes that are directly responsible for recurrence prediction. This proposed system has achieved
an average accuracy of 98.9% in predicting cancer recurrence over 3 datasets. The experimental results
demonstrate the efficacy of our framework.
Nanoparticle Based Targeting Approaches for Lung Cancer: A Mini ReviewAI Publications
Every year more than 10 million people are diagnosed with cancer and more than 6 million deaths – around 12% of deaths worldwide. The objective of cancer treatment still is to cure the patients if possible or prolong their life and improve their quality of life by surgical removal of the cancerous tissue, radiation therapy, biotherapy, chemotherapy, bone marrow transplant or a combination of some of these available treatments. This review aims to explore the various approaches using nanotechnology and surface decoration with ligands capable to target lung cancers.
Advances and Problems in Preclinical Models for Childhood Cancerijtsrd
Microblogging today has gotten an acclaimed specific instrument among Neuroblastoma is a sympathetic nervous system disease in children and is the most prevalent solid tumor in childhood, accounting for 15 of all pediatric oncology deaths. Nearly 80 of patients with this clinically active condition do not react to current treatments in the long run. The precise portrayal of tumor biology and diversity is the key obstacle in the discovery and evaluation of novel agents for pediatric drug growth. In addition to this restriction, the low prevalence of neuroblastoma renders it difficult to enroll qualifying patients for early phase clinical trials, emphasizing the importance of thorough preclinical studies to ensure that the right drugs are chosen. To address these issues, researchers need new preclinical models, technologies, and principles. Tissue engineering provides appealing methods for developing three dimensional 3D cell models utilizing different biomaterials and manufacturing techniques that replicate the geometry, dynamics, heterogeneity, metabolic gradients, and cell connectivity of the native tumor microenvironment. We address existing laboratory models and evaluate their ability to reflect the systemic organization and physiological conditions of the human body, as well as current and emerging strategies to recapitulate the tumor niche utilizing tissue engineered platforms in this study. Finally, well talk about how innovative 3Din vitroculture systems might be used to answer unanswered questions in neuroblastoma biology. V. Sah "Advances and Problems in Preclinical Models for Childhood Cancer" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021, URL: https://www.ijtsrd.compapers/ijtsrd42379.pdf Paper URL: https://www.ijtsrd.combiological-science/neurobiology/42379/advances-and-problems-in-preclinical-models-for-childhood-cancer/v-sah
This document summarizes a study conducted by the World Health Organization to standardize antibiotic sensitivity testing techniques. The study involved 16 laboratories testing the minimum inhibitory concentrations and inhibition zone sizes of 16 bacterial organisms using broth and agar dilution and agar diffusion methods. The results showed that the agar diffusion technique was the most reproducible. The working party then recommended standard reference techniques for performing the three types of tests based on their findings. They also proposed a 4-grade system for clinically reporting bacterial sensitivity results related to minimum inhibitory concentrations and attainable antibiotic levels in vivo.
TARGETED DRUG DELIVERY SYSTEM IN CANCER THERAPEUTICS: WITH SPECIAL FOCUS ON S...AnkushSharma400
Due to the mutations in the genes, cancer occurs and propagates to the other areas of the human body. The mutation in the tumor suppressor gene, as well as the oncogene, leads to the growth of a tumor. The RNA interference (RNAi) targets these genes by inducing gene silencing. Gene
silencing has been an attractive approach to stop the growth of cancer cells after the detection of RNA
interference (RNAi) in the animal cells.
The Global Cancer Vaccines Market size was USD 9.69 billion in 2023 and it is expected to grow to USD 17.86 billion in 2031 with a CAGR of 10.55% in the 2024-2031 period.
The Global Cancer Vaccines Market size was USD 9.69 billion in 2023 and it is expected to grow to USD 17.86 billion in 2031 with a CAGR of 10.55% in the 2024-2031 period.
A Novel Eclectic Approach for Cancer Therapy with Liquid Knife & Immuno Thera...CrimsonpublishersCancer
Recent years cancer immunological therapy is getting very popular and many new drug have been approved by FDA like PD1 and PDl-1, however, in clinical practice of cancer treatment, it looks very limited efficacy for advanced cancer, so that physician started to use comprehensive plan by combination chemotherapy with PD1 as a novel strategy with a better clinical benefit. Since chemotherapy and radiation therapy always produce the side effect like loss hair, vomit and neutropenia, and surgery is limited for many later stages of cancers, also surgery damages body shapes with functions, esophageal cancer was removed with reconstruction and put stomach into chest and stomach never has normal function; a lot of cases showed surgery can’t be performed because tumor location in special site, like tumor location in posterior vaginal wall or vaginal carnal, surgery just is not allowed to do the procedure, if remove the tumor in these location, it will make a hole to connect to the rectal. Because of the extremely toxic side effects, many cancer patients cannot be successfully completed a surgery or a complete course of chemotherapy or radiation therapy, and some cases even die from the side effects of surgery or chemotherapy or radiation therapy due to a patient’s poor tolerance.
Download Global cancer immunotherapy market outlook 2020KuicK Research
\"Global Cancer Immunotherapy Market Outlook 2020\" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Global cancer immunotherapy market outlook 2020KuicK Research
The document provides an overview of the global cancer immunotherapy market outlook for 2020. It discusses how cancer immunotherapies work by modulating the immune system to treat cancer. The market has seen significant growth with many approved and pipeline immunotherapies across classes like monoclonal antibodies, cytokines, vaccines, and immune checkpoint inhibitors. The market is expected to continue growing in coming years due to increased research and funding leading to new treatment modalities and biomarkers to expand the use of immunotherapies for additional cancer types.
This document is a thesis from the University of Strasbourg evaluating cell viability and apoptosis in the human pancreatic cancer cell line ASPC-1 using fungi extracts. It includes an introduction covering cancer, drug discovery, the cell cycle, apoptosis, cell culture techniques, cytometry, pancreatic cancer, and the ASPC-1 cell line. The main body describes methods, materials, protocols, results, and compares results to similar studies evaluating cell cycle analysis, viability assays, and apoptosis induction in ASPC-1 cells treated with fungi extracts.
The Recent advances in gene delivery using nanostructures and future prospectsAANBTJournal
This document summarizes recent advances in using nanostructures for gene delivery in gene therapy. It discusses the key challenges to effective gene therapy, including overcoming intracellular and extracellular barriers to delivery. It reviews the history of viral and non-viral gene delivery methods. Specifically, it describes several non-viral methods that have been developed using nanostructures, such as magnetic nanoparticles, PEGylated multi-component carriers, oligonucleotides, lipoplexes, polyplexes, and dendrimers. Overall, it finds that while viral methods remain more effective, recent advances in non-viral nanostructure-based delivery systems show promise for improving safety and effectiveness of gene therapy.
1. The document discusses using machine learning to optimize microfluidic platforms for cancer research. It reviews how microfluidics has been used for circulating tumor cell isolation and modeling tumor microenvironments.
2. Machine learning can help reveal the causality between different factors in cancer metastasis by analyzing large datasets from microfluidic experiments. This can help push research to a higher level.
3. The integration of machine learning and microfluidics, known as intelligent microfluidics, allows microfluidic platforms to reach their full potential by using machine learning techniques like feature extraction, classification, prediction, and optimization.
Nanotechnology in Targeted Drug Delivery.pdfAzeem Muhammed
This document discusses nanotechnology for targeted drug delivery and therapeutics. It describes how nanocarriers such as liposomes, polymeric nanoparticles, micelles, dendrimers, and hydrogels can be used as drug delivery platforms. These nanocarriers protect drugs, allow for controlled release, and can be modified for targeted delivery through conjugation of ligands. Many nanocarrier drug delivery systems are currently in clinical trials for applications such as cancer therapy and treatment of other diseases.
This white paper discusses improving the clinical development of cancer immunotherapies. It outlines the current immunotherapy landscape including checkpoint inhibitors, adoptive T cell therapies, cancer vaccines, and biomarkers. The paper emphasizes that while immunotherapy has promising results for some patients and cancer types, more research is needed to understand which patients will benefit most from which approaches and how to best leverage various immune system components in the fight against cancer. Operational considerations and cautions for clinical development are also discussed.
This document describes a new cancer therapy technique using tunable, monochromatic X-rays being developed by the company MXISystems. The technique shows promise in precisely targeting radiation therapy to cancer cells while sparing healthy tissue. However, commercializing the technology faces challenges including high capital costs, lack of supply chain for key components, and investor reluctance over perceived long-term risk. The document applies the framework of accelerated radical innovation to analyze MXISystems' innovation and determine how to accelerate its widespread clinical use by addressing challenges it faces in commercialization.
Global dendritic cell cancer vaccine market outlook 2020KuicK Research
“Global Dendritic Cell Cancer Vaccine Market Outlook 2020” Report highlights:
Introduction & Mechanism of Action of Dendritic Cells
New Vaccine Strategies That Exploit Dendritic Cells Biochemistry
Dendritic Cell Cancer Vaccine Market & Clinical Insight
Comparative Insight of Dendritic Cell Vaccines & Other Class of Vaccines
Dendritic Cell Cancer Vaccine Pipeline by Country, Company, Indication & Phase
Dendritic Cell Cancer Vaccine Clinical Pipeline: 58 Vaccines
Majority in Phase I/II & Phase II Clinical Trials: 12 Vaccines
1) The document discusses precision medicine in cancer treatment, which is a medical model that takes into account individual variability in genes, lifestyle, and environment to tailor treatment for each patient.
2) Precision medicine aims to improve cancer treatment outcomes by using biomarkers and genetic/molecular analysis to identify the specific causes of a patient's cancer and select targeted therapies.
3) This approach could help increase survival rates, reduce side effects, and improve overall treatment efficacy compared to traditional one-size-fits-all cancer care.
Cancer is one of the deadliest diseases in the world and is responsible for around 13% of all deaths worldwide.
Cancer incidence rate is growing at an alarming rate in the world. Despite the fact that cancer is
preventable and curable in early stages, the vast majority of patients are diagnosed with cancer very late.
Furthermore, cancer commonly comes back after years of treatment. Therefore, it is of paramount
importance to predict cancer recurrence so that specific treatments can be sought. Nonetheless,
conventional methods of predicting cancer recurrence rely solely on histopathology and the results are not
very reliable. The microarray gene expression technology is a promising technology that couldpredict
cancer recurrence by analyzing the gene expression of sample cells. The microarray technology allows
researchers to examine the expression of thousands of genes simultaneously. This paper describes a stateof-
the-art machine learning based approach called averaged one-dependence estimators with subsumption
resolution to tackle the problem of predicting, from DNA microarray gene expression data, whether a
particular cancer will recur within a specific timeframe, which is usually 5 years. To lower the
computational complexity, we employ an entropy-based geneselection approach to select relevant
prognosticgenes that are directly responsible for recurrence prediction. This proposed system has achieved
an average accuracy of 98.9% in predicting cancer recurrence over 3 datasets. The experimental results
demonstrate the efficacy of our framework.
Nanoparticle Based Targeting Approaches for Lung Cancer: A Mini ReviewAI Publications
Every year more than 10 million people are diagnosed with cancer and more than 6 million deaths – around 12% of deaths worldwide. The objective of cancer treatment still is to cure the patients if possible or prolong their life and improve their quality of life by surgical removal of the cancerous tissue, radiation therapy, biotherapy, chemotherapy, bone marrow transplant or a combination of some of these available treatments. This review aims to explore the various approaches using nanotechnology and surface decoration with ligands capable to target lung cancers.
Advances and Problems in Preclinical Models for Childhood Cancerijtsrd
Microblogging today has gotten an acclaimed specific instrument among Neuroblastoma is a sympathetic nervous system disease in children and is the most prevalent solid tumor in childhood, accounting for 15 of all pediatric oncology deaths. Nearly 80 of patients with this clinically active condition do not react to current treatments in the long run. The precise portrayal of tumor biology and diversity is the key obstacle in the discovery and evaluation of novel agents for pediatric drug growth. In addition to this restriction, the low prevalence of neuroblastoma renders it difficult to enroll qualifying patients for early phase clinical trials, emphasizing the importance of thorough preclinical studies to ensure that the right drugs are chosen. To address these issues, researchers need new preclinical models, technologies, and principles. Tissue engineering provides appealing methods for developing three dimensional 3D cell models utilizing different biomaterials and manufacturing techniques that replicate the geometry, dynamics, heterogeneity, metabolic gradients, and cell connectivity of the native tumor microenvironment. We address existing laboratory models and evaluate their ability to reflect the systemic organization and physiological conditions of the human body, as well as current and emerging strategies to recapitulate the tumor niche utilizing tissue engineered platforms in this study. Finally, well talk about how innovative 3Din vitroculture systems might be used to answer unanswered questions in neuroblastoma biology. V. Sah "Advances and Problems in Preclinical Models for Childhood Cancer" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021, URL: https://www.ijtsrd.compapers/ijtsrd42379.pdf Paper URL: https://www.ijtsrd.combiological-science/neurobiology/42379/advances-and-problems-in-preclinical-models-for-childhood-cancer/v-sah
This document summarizes a study conducted by the World Health Organization to standardize antibiotic sensitivity testing techniques. The study involved 16 laboratories testing the minimum inhibitory concentrations and inhibition zone sizes of 16 bacterial organisms using broth and agar dilution and agar diffusion methods. The results showed that the agar diffusion technique was the most reproducible. The working party then recommended standard reference techniques for performing the three types of tests based on their findings. They also proposed a 4-grade system for clinically reporting bacterial sensitivity results related to minimum inhibitory concentrations and attainable antibiotic levels in vivo.
TARGETED DRUG DELIVERY SYSTEM IN CANCER THERAPEUTICS: WITH SPECIAL FOCUS ON S...AnkushSharma400
Due to the mutations in the genes, cancer occurs and propagates to the other areas of the human body. The mutation in the tumor suppressor gene, as well as the oncogene, leads to the growth of a tumor. The RNA interference (RNAi) targets these genes by inducing gene silencing. Gene
silencing has been an attractive approach to stop the growth of cancer cells after the detection of RNA
interference (RNAi) in the animal cells.
The Global Cancer Vaccines Market size was USD 9.69 billion in 2023 and it is expected to grow to USD 17.86 billion in 2031 with a CAGR of 10.55% in the 2024-2031 period.
The Global Cancer Vaccines Market size was USD 9.69 billion in 2023 and it is expected to grow to USD 17.86 billion in 2031 with a CAGR of 10.55% in the 2024-2031 period.
A Novel Eclectic Approach for Cancer Therapy with Liquid Knife & Immuno Thera...CrimsonpublishersCancer
Recent years cancer immunological therapy is getting very popular and many new drug have been approved by FDA like PD1 and PDl-1, however, in clinical practice of cancer treatment, it looks very limited efficacy for advanced cancer, so that physician started to use comprehensive plan by combination chemotherapy with PD1 as a novel strategy with a better clinical benefit. Since chemotherapy and radiation therapy always produce the side effect like loss hair, vomit and neutropenia, and surgery is limited for many later stages of cancers, also surgery damages body shapes with functions, esophageal cancer was removed with reconstruction and put stomach into chest and stomach never has normal function; a lot of cases showed surgery can’t be performed because tumor location in special site, like tumor location in posterior vaginal wall or vaginal carnal, surgery just is not allowed to do the procedure, if remove the tumor in these location, it will make a hole to connect to the rectal. Because of the extremely toxic side effects, many cancer patients cannot be successfully completed a surgery or a complete course of chemotherapy or radiation therapy, and some cases even die from the side effects of surgery or chemotherapy or radiation therapy due to a patient’s poor tolerance.
Download Global cancer immunotherapy market outlook 2020KuicK Research
\"Global Cancer Immunotherapy Market Outlook 2020\" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Global cancer immunotherapy market outlook 2020KuicK Research
The document provides an overview of the global cancer immunotherapy market outlook for 2020. It discusses how cancer immunotherapies work by modulating the immune system to treat cancer. The market has seen significant growth with many approved and pipeline immunotherapies across classes like monoclonal antibodies, cytokines, vaccines, and immune checkpoint inhibitors. The market is expected to continue growing in coming years due to increased research and funding leading to new treatment modalities and biomarkers to expand the use of immunotherapies for additional cancer types.
This document is a thesis from the University of Strasbourg evaluating cell viability and apoptosis in the human pancreatic cancer cell line ASPC-1 using fungi extracts. It includes an introduction covering cancer, drug discovery, the cell cycle, apoptosis, cell culture techniques, cytometry, pancreatic cancer, and the ASPC-1 cell line. The main body describes methods, materials, protocols, results, and compares results to similar studies evaluating cell cycle analysis, viability assays, and apoptosis induction in ASPC-1 cells treated with fungi extracts.
The Recent advances in gene delivery using nanostructures and future prospectsAANBTJournal
This document summarizes recent advances in using nanostructures for gene delivery in gene therapy. It discusses the key challenges to effective gene therapy, including overcoming intracellular and extracellular barriers to delivery. It reviews the history of viral and non-viral gene delivery methods. Specifically, it describes several non-viral methods that have been developed using nanostructures, such as magnetic nanoparticles, PEGylated multi-component carriers, oligonucleotides, lipoplexes, polyplexes, and dendrimers. Overall, it finds that while viral methods remain more effective, recent advances in non-viral nanostructure-based delivery systems show promise for improving safety and effectiveness of gene therapy.
Similar to Revolutionizing Medicine: Breakthrough Cell-Based Delivery System for Targeted Therapy Unveiled. (20)
Travis Hills of MN is Making Clean Water Accessible to All Through High Flux ...Travis Hills MN
By harnessing the power of High Flux Vacuum Membrane Distillation, Travis Hills from MN envisions a future where clean and safe drinking water is accessible to all, regardless of geographical location or economic status.
The debris of the ‘last major merger’ is dynamically youngSérgio Sacani
The Milky Way’s (MW) inner stellar halo contains an [Fe/H]-rich component with highly eccentric orbits, often referred to as the
‘last major merger.’ Hypotheses for the origin of this component include Gaia-Sausage/Enceladus (GSE), where the progenitor
collided with the MW proto-disc 8–11 Gyr ago, and the Virgo Radial Merger (VRM), where the progenitor collided with the
MW disc within the last 3 Gyr. These two scenarios make different predictions about observable structure in local phase space,
because the morphology of debris depends on how long it has had to phase mix. The recently identified phase-space folds in Gaia
DR3 have positive caustic velocities, making them fundamentally different than the phase-mixed chevrons found in simulations
at late times. Roughly 20 per cent of the stars in the prograde local stellar halo are associated with the observed caustics. Based
on a simple phase-mixing model, the observed number of caustics are consistent with a merger that occurred 1–2 Gyr ago.
We also compare the observed phase-space distribution to FIRE-2 Latte simulations of GSE-like mergers, using a quantitative
measurement of phase mixing (2D causticality). The observed local phase-space distribution best matches the simulated data
1–2 Gyr after collision, and certainly not later than 3 Gyr. This is further evidence that the progenitor of the ‘last major merger’
did not collide with the MW proto-disc at early times, as is thought for the GSE, but instead collided with the MW disc within
the last few Gyr, consistent with the body of work surrounding the VRM.
The binding of cosmological structures by massless topological defectsSérgio Sacani
Assuming spherical symmetry and weak field, it is shown that if one solves the Poisson equation or the Einstein field
equations sourced by a topological defect, i.e. a singularity of a very specific form, the result is a localized gravitational
field capable of driving flat rotation (i.e. Keplerian circular orbits at a constant speed for all radii) of test masses on a thin
spherical shell without any underlying mass. Moreover, a large-scale structure which exploits this solution by assembling
concentrically a number of such topological defects can establish a flat stellar or galactic rotation curve, and can also deflect
light in the same manner as an equipotential (isothermal) sphere. Thus, the need for dark matter or modified gravity theory is
mitigated, at least in part.
(June 12, 2024) Webinar: Development of PET theranostics targeting the molecu...Scintica Instrumentation
Targeting Hsp90 and its pathogen Orthologs with Tethered Inhibitors as a Diagnostic and Therapeutic Strategy for cancer and infectious diseases with Dr. Timothy Haystead.
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...Sérgio Sacani
Context. With a mass exceeding several 104 M⊙ and a rich and dense population of massive stars, supermassive young star clusters
represent the most massive star-forming environment that is dominated by the feedback from massive stars and gravitational interactions
among stars.
Aims. In this paper we present the Extended Westerlund 1 and 2 Open Clusters Survey (EWOCS) project, which aims to investigate
the influence of the starburst environment on the formation of stars and planets, and on the evolution of both low and high mass stars.
The primary targets of this project are Westerlund 1 and 2, the closest supermassive star clusters to the Sun.
Methods. The project is based primarily on recent observations conducted with the Chandra and JWST observatories. Specifically,
the Chandra survey of Westerlund 1 consists of 36 new ACIS-I observations, nearly co-pointed, for a total exposure time of 1 Msec.
Additionally, we included 8 archival Chandra/ACIS-S observations. This paper presents the resulting catalog of X-ray sources within
and around Westerlund 1. Sources were detected by combining various existing methods, and photon extraction and source validation
were carried out using the ACIS-Extract software.
Results. The EWOCS X-ray catalog comprises 5963 validated sources out of the 9420 initially provided to ACIS-Extract, reaching a
photon flux threshold of approximately 2 × 10−8 photons cm−2
s
−1
. The X-ray sources exhibit a highly concentrated spatial distribution,
with 1075 sources located within the central 1 arcmin. We have successfully detected X-ray emissions from 126 out of the 166 known
massive stars of the cluster, and we have collected over 71 000 photons from the magnetar CXO J164710.20-455217.
CLASS 12th CHEMISTRY SOLID STATE ppt (Animated)eitps1506
Description:
Dive into the fascinating realm of solid-state physics with our meticulously crafted online PowerPoint presentation. This immersive educational resource offers a comprehensive exploration of the fundamental concepts, theories, and applications within the realm of solid-state physics.
From crystalline structures to semiconductor devices, this presentation delves into the intricate principles governing the behavior of solids, providing clear explanations and illustrative examples to enhance understanding. Whether you're a student delving into the subject for the first time or a seasoned researcher seeking to deepen your knowledge, our presentation offers valuable insights and in-depth analyses to cater to various levels of expertise.
Key topics covered include:
Crystal Structures: Unravel the mysteries of crystalline arrangements and their significance in determining material properties.
Band Theory: Explore the electronic band structure of solids and understand how it influences their conductive properties.
Semiconductor Physics: Delve into the behavior of semiconductors, including doping, carrier transport, and device applications.
Magnetic Properties: Investigate the magnetic behavior of solids, including ferromagnetism, antiferromagnetism, and ferrimagnetism.
Optical Properties: Examine the interaction of light with solids, including absorption, reflection, and transmission phenomena.
With visually engaging slides, informative content, and interactive elements, our online PowerPoint presentation serves as a valuable resource for students, educators, and enthusiasts alike, facilitating a deeper understanding of the captivating world of solid-state physics. Explore the intricacies of solid-state materials and unlock the secrets behind their remarkable properties with our comprehensive presentation.
When I was asked to give a companion lecture in support of ‘The Philosophy of Science’ (https://shorturl.at/4pUXz) I decided not to walk through the detail of the many methodologies in order of use. Instead, I chose to employ a long standing, and ongoing, scientific development as an exemplar. And so, I chose the ever evolving story of Thermodynamics as a scientific investigation at its best.
Conducted over a period of >200 years, Thermodynamics R&D, and application, benefitted from the highest levels of professionalism, collaboration, and technical thoroughness. New layers of application, methodology, and practice were made possible by the progressive advance of technology. In turn, this has seen measurement and modelling accuracy continually improved at a micro and macro level.
Perhaps most importantly, Thermodynamics rapidly became a primary tool in the advance of applied science/engineering/technology, spanning micro-tech, to aerospace and cosmology. I can think of no better a story to illustrate the breadth of scientific methodologies and applications at their best.
JAMES WEBB STUDY THE MASSIVE BLACK HOLE SEEDSSérgio Sacani
The pathway(s) to seeding the massive black holes (MBHs) that exist at the heart of galaxies in the present and distant Universe remains an unsolved problem. Here we categorise, describe and quantitatively discuss the formation pathways of both light and heavy seeds. We emphasise that the most recent computational models suggest that rather than a bimodal-like mass spectrum between light and heavy seeds with light at one end and heavy at the other that instead a continuum exists. Light seeds being more ubiquitous and the heavier seeds becoming less and less abundant due the rarer environmental conditions required for their formation. We therefore examine the different mechanisms that give rise to different seed mass spectrums. We show how and why the mechanisms that produce the heaviest seeds are also among the rarest events in the Universe and are hence extremely unlikely to be the seeds for the vast majority of the MBH population. We quantify, within the limits of the current large uncertainties in the seeding processes, the expected number densities of the seed mass spectrum. We argue that light seeds must be at least 103 to 105 times more numerous than heavy seeds to explain the MBH population as a whole. Based on our current understanding of the seed population this makes heavy seeds (Mseed > 103 M⊙) a significantly more likely pathway given that heavy seeds have an abundance pattern than is close to and likely in excess of 10−4 compared to light seeds. Finally, we examine the current state-of-the-art in numerical calculations and recent observations and plot a path forward for near-future advances in both domains.
Describing and Interpreting an Immersive Learning Case with the Immersion Cub...Leonel Morgado
Current descriptions of immersive learning cases are often difficult or impossible to compare. This is due to a myriad of different options on what details to include, which aspects are relevant, and on the descriptive approaches employed. Also, these aspects often combine very specific details with more general guidelines or indicate intents and rationales without clarifying their implementation. In this paper we provide a method to describe immersive learning cases that is structured to enable comparisons, yet flexible enough to allow researchers and practitioners to decide which aspects to include. This method leverages a taxonomy that classifies educational aspects at three levels (uses, practices, and strategies) and then utilizes two frameworks, the Immersive Learning Brain and the Immersion Cube, to enable a structured description and interpretation of immersive learning cases. The method is then demonstrated on a published immersive learning case on training for wind turbine maintenance using virtual reality. Applying the method results in a structured artifact, the Immersive Learning Case Sheet, that tags the case with its proximal uses, practices, and strategies, and refines the free text case description to ensure that matching details are included. This contribution is thus a case description method in support of future comparative research of immersive learning cases. We then discuss how the resulting description and interpretation can be leveraged to change immersion learning cases, by enriching them (considering low-effort changes or additions) or innovating (exploring more challenging avenues of transformation). The method holds significant promise to support better-grounded research in immersive learning.